Source comparison
CJC-1295 No DAC Comparison: Safety Profile vs Other GH Secretagogues
CJC-1295 no DAC GHRH receptor agonist <30 minutes (peptide), 2–3 hour GH pulse Injection-site reactions (22%), headaches (18%), flushing (12%) Low. Transient hypoglycaemia risk in glucose-impaired subjects Best choice for pulsatile GH elevation with minimal ch
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC
- GHRH receptor agonist
- <30 minutes (peptide), 2–3 hour GH pulse
- Injection-site reactions (22%), headaches (18%), flushing (12%)
- Low. Transient hypoglycaemia risk in glucose-impaired subjects
- Best choice for pulsatile GH elevation with minimal chronic accumulation. Safer than DAC variant for extended protocols
- CJC-1295 with DAC
- GHRH receptor agonist + lysine extension
- 6–8 days
- Water retention (30–40%), joint pain (15–25%), insulin resistance markers
- Moderate. Prolonged IGF-1 elevation increases joint inflammation and glucose dysregulation risk
- Higher cumulative GH exposure. Appropriate for infrequent dosing but requires monitoring for acromegaly-like symptoms
- Ipamorelin
- Ghrelin receptor agonist
- 2 hours
- Headaches (10–15%), transient hunger (20–30%), mild water retention
- Very low. Highly selective for GH release without cortisol or prolactin elevation
- Safest standalone secretagogue. Often stacked with CJC no DAC for synergistic pulsatile release
- GHRP-2
- 20–30 minutes
- Intense hunger (40–50%), cortisol spike (15–20% above baseline), flushing
- Low to moderate. Cortisol elevation problematic for evening dosing or high-stress subjects
- Effective but less selective. Cortisol elevation limits use in cortisol-sensitive protocols
- MK-677
- Oral ghrelin mimetic
- 24 hours
- Persistent hunger (60–70%), water retention (30–40%), fasting glucose elevation
- Moderate. Chronic daily elevation of GH and insulin can impair glucose tolerance over 12+ weeks
- Convenient oral dosing but poorest safety profile for metabolic health. Not pulsatile